Exploration of Tolerability and Dose Responses for a Yeast-based Probiotic
The purpose of this study is to evaluate the tolerability and efficacy of a yeast-based dietary supplement on gastrointestinal, mental, and skin health. Yeasts are naturally present on fruits and plants, and are used to bake bread, beer and wine. Some of these yeasts are commonly consumed and may actually benefit your gut health. The supplemental yeast could strengthen the gut lining or help good bacteria in the gut grow better.
In this study, the investigators will look at how two doses of a yeast-based supplement impacts gut health, bowel movement consistency, and mental health. The study will last 17 weeks and consist of 7 clinic visits (1 screening visit and 6 test visits).
調査の概要
状態
詳細な説明
This study will take place at Colorado State University in Fort Collins, Colorado, USA. It will last approximately 17 weeks. This is a randomized, double-blind 3-arm crossover study with three treatments (placebo and two doses of Pichia kluyveri). The treatments will be taken for 4 weeks in a random order by every participant. Each treatment phase is separated by a 2-week washout. The first visit is a screening visit, where investigators will determine eligibility. Visit 2-7 are test visits where investigators will collect information on height, weight, waist, and hip measurements. Blood pressure will also be measured and the visit will conclude with a venous blood draw. During this visit, participants will also complete questionnaires about gut, mental, and skin health, menopause symptoms, and physical activity. A stool sample and bowel movement and diet records will be completed at home.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Jenny Whittington, MS
- 電話番号:970-310-6843
- メール:ijwhitt@rams.colostate.edu
研究連絡先のバックアップ
- 名前:Tiffany L Weir, PhD
- 電話番号:970-215-7571
- メール:tiffany.weir@colostate.edu
研究場所
-
-
Colorado
-
Fort Collins、Colorado、アメリカ、80521
- Colorado State University
-
主任研究者:
- Tiffany Weir, PhD
-
コンタクト:
- Tiffany Weir, PhD
- 電話番号:970-215-7571
- メール:tiffany.weir@colostate.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- between 18-75 years old
- BMI <30 kg/m2
- mild/moderate gastrointestinal distress
Exclusion Criteria:
- Have taken antibiotics within two months of enrollment in the study
- Are currently taking statins, metformin, NSAIDs, and MAO inhibitors or other medications that could interfere with study outcomes, as determined by the study PI
- Have a current diagnosis of cancer, liver or kidney disease, gastrointestinal diseases (including Celiac, Crohn's, Ulcerative Colitis), and cardiometabolic disorders (cardiovascular disease, diabetes, etc.)
- Are pregnant or breastfeeding, or actively trying to lose weight
- Use excessive alcohol
- Use of supplements containing probiotics at any dose or if you are participating in other studies that may interfere with the bacteria in your gut.
- Unable or unwilling to consume capsules, provide stool or blood samples, track bowel movements and symptoms, and attend scheduled clinic visits.
- Have allergies to study treatments or medical supplies (eg. Latex, yeast, cellulose)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
Placebo - cellulose and hypromellose |
|
実験的:Pichia kluyveri 9.9 x 10^7
|
9.9 x 10^7 Pichia kluyveri in microcrystalline cellulose and hypromellose |
|
実験的:Pichia kluyveri 1 x 10^8
|
1 x 10^8 Pichia kluyveri in microcrystalline cellulose and hypromellose |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Severity of gastrointestinal symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
時間枠:4 weeks
|
The Gastrointestinal Symptom Rating Scale (GSRS) is a widely used tool for measuring gastrointestinal symptoms across five domains. The GSRS is scored between "No discomfort" and "Very severe discomfort" |
4 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Systemic inflammation indicated by circulating Tumor Necrosis Factor Alpha
時間枠:4 weeks
|
Tumor necrosis factor alpha, or TNF-a, is an inflammatory cytokine that is implicated in many diseases. |
4 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 8533
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。